Riccardo Polosa is the Founder of the Center of Excellence for the acceleration of HArm Reduction (CoEHAR - University of Catania, Italy). Dr Polosa is Full Professor of Internal Medicine for the same University and Director of the Center for Smoking Prevention and Treatment at the University Hospital "Policlinico-V. Emanuele” of Catania. Dr. Polosa and the CoEHAR team of researchers conduct several high-profile clinical and behavioral research in the field of smoking-related diseases. According to a bibliometric analysis, Professor Polosa is considered the most productive scientist in the world in the field of electronic cigarette research.

Dr. Moira Gilchrist leads the global strategic and scientific communications for Philip Morris International (PMI). From bringing to life PMI’s fast-pace progress as it evolves into a smoke-free business and expands in areas outside the tobacco and nicotine space, to translating the science behind PMI’s smoke-free alternatives into information that policymakers and the public can easily understand, Moira and her team are at the heart of the company’s historic evolution. She regularly engages with public health authorities, media, and decision-makers around the world, demonstrating the benefits of scientifically substantiated, smoke-free products for those adults who would otherwise continue smoking and calling for risk-proportionate regulation that affords these people accurate information about and access to these better alternatives. In short, she plays a vital role in PMI’s transition away from cigarettes and its journey toward a better, smoke-free future.

Prior to her current role, Moira held several positions within PMI, including leading the
Reduced-Risk Products Corporate Affairs team, serving as director of Scientific
Engagement within the R&D function, and working in both product development and
commercialization.
Before joining PMI in 2006, Moira worked in the pharmaceutical sector for more than a
decade. She was a principal consultant within PwC’s and IBM’s pharmaceutical industry
consulting groups and held positions within both industry and nonprofit organizations as
a developer of drug formulations.
Moira holds a degree in Pharmacy and a PhD in Pharmaceutical Sciences, both from the
University of Strathclyde in Glasgow, Scotland.

Christopher Russell, Ph.D. is a psychologist and Director of Russell Burnett Research &

Consultancy Ltd (RBRC), a contract research organization that specializes in the design,

conduct, and reporting of perception and behavioral studies of the potential population health

risks and benefits of candidate tobacco harm reduction (THR) products, such as ENDS,

heated tobacco products, and modern oral tobacco products. RBRC designs studies to

characterize adults’ use and perceptions of new tobacco products, longitudinal tobacco

product use transitions, and understanding of product labels, labelling, and marketing

materials. Results of these studies help to inform PMTA, MRTPA, and other applicable

regulatory assessments of the potential impact of candidate THR products on future tobacco

use behavior and population health.

David Sweanor is an adjunct professor, Faculty of Law, and chair of the advisory board of the Centre for Health Law, Policy & Ethics at the University of Ottawa and has been actively involved in tobacco and health policy issues since the beginning of the 1980s. He has worked globally, and with numerous groups, including the International Union Against Cancer, World Health Organization, World Bank and the Pan American Health Organization and played a key role in achieving many global precedents in tobacco policy. He currently focuses much of his tobacco and nicotine related efforts on risk reduction strategies.

Christopher Russell, Ph.D. is a psychologist and Director of Russell Burnett Research &

Consultancy Ltd (RBRC), a contract research organization that specializes in the design,

conduct, and reporting of perception and behavioral studies of the potential population health

risks and benefits of candidate tobacco harm reduction (THR) products, such as ENDS,

heated tobacco products, and modern oral tobacco products. RBRC designs studies to

characterize adults’ use and perceptions of new tobacco products, longitudinal tobacco

product use transitions, and understanding of product labels, labelling, and marketing

materials. Results of these studies help to inform PMTA, MRTPA, and other applicable

regulatory assessments of the potential impact of candidate THR products on future tobacco

use behavior and population health.

Marewa Glover is director of the independent Centre of Research Excellence: Indigenous Sovereignty & Smoking based in Auckland, New Zealand. Funded by the Foundation for a Smoke-Free World, the center aims to reduce the harms associated with tobacco use among all indigenous people globally. Glover is also tobacco section editor for the international Harm Reduction Journal.

As a behavioral scientist, Glover has led and collaborated on many studies resulting in more than 100 scientific publications. In 2019, she was one of three finalists for the prestigious New Zealander of the Year Award in recognition of her dedication to reducing tobacco smoking harm over the past 30 years and advocating for a harm-reduction approach to combustible cigarette smoking.

In June 2019, Glover won awards for Best Picture and Best Director at the Global Forum on Nicotine in Warsaw, Poland, for a short video series that she wrote and commissioned. At the 2018 Global Forum on Nicotine Glover received the Outstanding Advocate award from the International Network of Nicotine Consumer Organizations. Glover is a former professor of public health at Massey University and a former chair of End Smoking NZ, a charitable trust that has lobbied for tobacco harm reduction for more than a decade.

David Sweanor is an adjunct professor, Faculty of Law, and chair of the advisory board of the Centre for Health Law, Policy & Ethics at the University of Ottawa and has been actively involved in tobacco and health policy issues since the beginning of the 1980s. He has worked globally, and with numerous groups, including the International Union Against Cancer, World Health Organization, World Bank and the Pan American Health Organization and played a key role in achieving many global precedents in tobacco policy. He currently focuses much of his tobacco and nicotine related efforts on risk reduction strategies.

Konstantinos Farsalinos, MD, MPH is a physician and senior researcher at the University of Patras and the School of Public Health-University of West Attica in Greece. His field of expertise is Public Health. He has been conducting laboratory, clinical and epidemiological research on smoking, tobacco harm reduction and e-cigarettes as principal investigator since 2011. He authored the first systematic review on e-cigarette safety/risk profile, published in 2014. Additionally, he has performed research and published studies on heated tobacco products. His findings have been presented in major international scientific congresses and his studies were used in preparing the regulatory framework on e-cigarettes by the European Union. As of mid-2020, he has published more than 90 studies and articles in international peer-reviewed scientific journals about smoking, tobacco harm reduction and alternative-to-smoking nicotine products. He was the handling editor and author of a book titled "Analytical assessment of e-cigarettes", published by Elsevier in 2017. In November 2020, he was declared a Highly Cited Researcher 2019 by the Web of Science, a list of researchers (6200 scientists out of 9 million examined) with the highest impact in global science in 21 scientific fields in the past decade. During the COVID-19 pandemic, he has published 6 peer-reviewed studies and several pre-prints about the COVID-19, including the association between smoking, nicotine and COVID-19.

CECILIA KINDSTRAND-ISAKSSON, SWEDEN Cecilia Kindstrand is Director of Public Affairs for Swedish Match, a company with tobacco harm reduction at the core of its business. The company divested its cigarette business in 1999 and is now offering products that are recognized as safer alternatives to cigarettes. She is based in Brussels and has worked extensively with the EU regulatory matters, especially the TPD 2014/40 a legislation banning the ‘proof of concept’ of tobacco harm reduction in 26 of the 27 Member States.

Barnaby Page is editorial director of Tamarind Intelligence, the publisher of ECigIntelligence, TobaccoIntelligence and CannIntelligence. As a journalist he has been covering the worldwide reduced-risk nicotine sector since 2014, with a particular focus on public health and regulatory issues; in his current role he manages Tamarind’s editorial and reporting teams, producing a wide range of nicotine-related content. He has been participating in the Global Forum on Nicotine since its inception.
Before coming into this field, Barnaby spent 30 years as a reporter and editor for newspapers, magazines and online services, specialising in technology and business. He is based near London.

Clive Bates has had a diverse career in the public, private and not-for-profit sectors. Starting out with IBM, he then switched career to work in the environment movement. From 1997-2003 he was Director of Action on Smoking and Health (UK), campaigning to reduce the harms caused by tobacco. In 2003 he joined Prime Minister Tony Blair’s Strategy Unit as a civil servant and worked in senior roles in the public sector and for the United Nations in Sudan. He is now Director of The Counterfactual, a consulting and advocacy practice focussed on a pragmatic approach to sustainability and public health.  

Scott J. Leischow, Ph.D. joined the Mayo Clinic in 2012, where he leads the Research on Health Equity and Community Health (REACH) Program at Mayo Clinic Arizona, and co-leads Cancer Prevention and Control within the Mayo Clinic Cancer Center. He was formerly University of Arizona and also served as Senior Advisor for Tobacco Policy in the US Department of Health and Human Services and Chief of the Tobacco Control Research Branch at the National Cancer Institute of NIH. Dr. Leischow completed his doctorate in Health Education from the University of Maryland, and a postdoctoral fellowship in Behavioral Pharmacology from Johns Hopkins University. Dr. Leischow has received several awards, including the NIH Director’s Award. Most of Dr. Leischow’s research and publications focus on pharmacologic and behavioral treatments for tobacco dependence, along with systems and network approaches to public health. Dr. Leischow is past President of the Society for Research on Nicotine and Tobacco (SRNT).

Colin Mendelsohn has worked as a medical practitioner, academic and researcher in smoking cessation and tobacco harm reduction for 40 years. He is the Founding Chairman of the Australian Tobacco Harm Reduction Association and was a Conjoint Associate Professor in the School of Public Health and Community Medicine at the University of New South Wales. He is a member of the expert advisory group that develops the Royal Australian College of General Practitioners’ national smoking cessation guidelines. He is actively involved in teaching, writing, researching and advocating for tobacco harm reduction.

David Sweanor is an adjunct professor, Faculty of Law, and chair of the advisory board of the Centre for Health Law, Policy & Ethics at the University of Ottawa and has been actively involved in tobacco and health policy issues since the beginning of the 1980s. He has worked globally, and with numerous groups, including the International Union Against Cancer, World Health Organization, World Bank and the Pan American Health Organization and played a key role in achieving many global precedents in tobacco policy. He currently focuses much of his tobacco and nicotine related efforts on risk reduction strategies.

Riccardo Polosa is the Founder of the Center of Excellence for the acceleration of HArm Reduction (CoEHAR - University of Catania, Italy). Dr Polosa is Full Professor of Internal Medicine for the same University and Director of the Center for Smoking Prevention and Treatment at the University Hospital "Policlinico-V. Emanuele” of Catania. Dr. Polosa and the CoEHAR team of researchers conduct several high-profile clinical and behavioral research in the field of smoking-related diseases. According to a bibliometric analysis, Professor Polosa is considered the most productive scientist in the world in the field of electronic cigarette research.